Portfolio

4SC

4SC develops orally available small molecule drugs for the treatment of cancer and autoimmune diseases focusing on epigenetic targets.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website

Actelion

Actelion went public on the Swiss Stock Exchange in 2000. It had a market cap of around CHF17B before its acquisition in 2017 by J&J for US$30B.

Location: Switzerland

Wellington contact: Rainer Strohmenger

Go to website

Adrenomed

Adrenomed develops a first-in-class monoclonal antibody (Adrecizumab) that targets the vasoactive Adrenomedullin system as a new strategy for causative and safe treatment of acute circulatory failure, e.g. septic shock.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website

Atopix

Atopix was acquired by Chiesi Farmaceutici in 2016 for more than €75M.

Location: United Kingdom

Wellington contact: Regina Hodits

Go to website

AyoxxA

Ayoxxa markets its innovative, patented beads-on-a-chip technology (LUNARIS™) to analyze multiple biomarkers in very low volume biological samples.

Location: Germany

Wellington contact: Regina Hodits

Go to website

Carisma Therapeutics

Carisma Therapeutics is pioneering the development of novel immunotherapies based on CAR macrophages.

Location: USA

Wellington contact: Regina Hodits

Go to website

confo therapeutics

Confo utilizes pioneering G protein-coupled receptor (GPCR) technology to build up a portfolio of first-in-class programs addressing difficult-to-drug disease targets in high need indications in neurology and beyond.

Location: Belgium

Wellington contact: Marianne Mertens, Regina Hodits

Go to website

Definiens

Definiens was acquired by MedImmune in 2015 for US$150M plus earnouts.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website

Endostim

EndoStim is marketing a device for the treatment of Gastro-esophageal Reflux Disease (GERD), commonly known as acid reflux, via electrical stimulation of the lower esophageal sphincter.

Location: USA

Wellington contact: Regina Hodits

Go to website

Evolva

Evolva (SWX: EVE) is focused on discovering, producing and supplying innovative, sustainable ingredients for health, wellness and nutrition.

Location: Switzerland

Wellington contact: Erich Schlick

Go to website

Genkyotex

Genkyotex (EPA: GKTX) is developing first-in-class selective inhibitors of NOX enzymes for an orphan fibrotic disease as well as for angiogenesis, pain and inflammation.

Location: France

Wellington contact: Rainer Strohmenger

Go to website

Grandis Biotech

Grandis was acquired in 2000 by Novartis.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website

GTX medical

GTX medical develops Targeted Epidural Spinal Stimulation (TESS), an implantable stimulation system and a robot-assisted training program to rehabilitate individuals with spinal cord injury.

Location: The Netherlands & Switzerland

Wellington contact: Regina Hodits

Go to website

Imevax

ImevaX develops a novel therapeutic vaccine for treatment of Helicobacter pylori, the cause of gastric cancer, by targeting essential bacterial immune evasion factors.

Location: Germany

Wellington contact: Erich Schlick

Go to website

Immatics

Immatics is developing Adoptive Cell Therapy (ACT) and soluble T cell receptor (sTCR) approaches based on the company's unrivalled XPRESIDENT cancer target discovery platform.

Location: Germany

Wellington contact: Erich Schlick

Go to website

Implanet Partners

Implanet specializes in development and commercialization of proprietary orthopedic implants with a focus on spine (JAZZ platform) and knee.

Location: France

Wellington contact: Rainer Strohmenger

Go to website

invendo

invendo was acquired in 2017 by Ambu A/S for up to €225M.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website

iOmx

iOmx is a next-generation immuno-oncology company focused on novel pathways for T cell evasion by cancer.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website

Middle Peak Medical

Middle Peak Medical is developing new minimally invasive, catheter-based treatment options for mitral valve disease. It was acquired by Symetis in 2017.

Location: Germany

Wellington contact: Regina Hodits

Go to website

mtm laboratories

mtm labs was acquired by Roche in 2011 for up to US$273M.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website

Neuway Pharma

NEUWAY Pharma is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website

NoemaLife

NoemaLife went public on Borsa Italiana in 2006.

Location: Italy

Wellington contact: Rainer Strohmenger

Go to website

Oxford Immunotec

Oxford Immunotec (NASDAQ: OXFD) focuses on developing and commercializing proprietary tests for latent tuberculosis and management of immune-regulated conditions.

Location: United Kingdom

Wellington contact: Rainer Strohmenger

Go to website

Polares Medical

Polares Medical SA develops a novel mitral valve repair system which can be implanted minimally invasively.

Location: USA

Wellington contact: Regina Hodits

Go to website

Quanta Dialysis Technologies

Quanta is developing and marketing easy-to-use and portable haemodialysis systems with full clinical performance for use in the home and clinic.

Location: United Kingdom

Wellington contact: Rainer Strohmenger

Go to website

Rigontec

Rigontec was acquired by Merck & Co. in 2017 for up to US$553M.

Location: Germany

Wellington contact: Regina Hodits

Go to website

Sapiens Steering Brain Stimulation

Sapiens was acquired by Medtronic in 2014 for US$200M.

Location: Netherlands

Wellington contact: Regina Hodits

Go to website

Sensimed

Sensimed has developed a digital contact lens with telemetry features - the Triggerfish® - that provides automated 24h recording of continuous ocular dimensional / intraocular pressure changes for Glaucoma management.

Location: Switzerland

Wellington contact: Erich Schlick

Go to website

SNIPR BIOME

SNIPR BIOME develops CRISPR-based drug candidates for difficult-to-treat infections and microbiome engineering in auto-immune and malignant disorders.

Location: Denmark

Wellington contact: Regina Hodits, Marianne Mertens

Go to website

Sphingotec

sphingotec develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website

Supersonic Imagine

SuperSonic Imagine (EPA:SSI) markets a unique imaging system combining shear wave elastography with conventional ultrasound, a new method to visualize soft tissues and diffentiate malignant from normal tissues at early tumor stages.

Location: France

Wellington contact: Erich Schlick

Go to website

Symetis

Symetis was acquired by Boston Scientific in 2017 for US$435M.

Location: Switzerland

Wellington contact: Erich Schlick

Go to website

Technolas Perfect Vision

Technolas Perfect Vision was acquired by Bausch & Lomb in 2013 for more than US$400M.

Location: Germany

Wellington contact: Rainer Stromenger

Go to website

Themis Bioscience

Themis is developing vaccines to prevent infectious diseases based on its Themaxyn™ platform with an emphasis on emerging tropical diseases and large unmet need indications.

Location: Austria

Wellington contact: Regina Hodits

Go to website

TRiCares

TRiCares is developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.

Location: Germany/France

Wellington contact: Christian Jung

Go to website

UroMems

Uromems is developing an active implantable medical device for treating male and female stress urinary incontinence.

Location: France

Wellington contact: Rainer Strohmenger

Go to website

Wavelight

Wavelight went public on the Frankfurt Stock Exchange in 1999 and was acquired by Alcon in 2007 for more than US$90M.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website